
    
      Thisi is a multi-center, double-blind, active-controlled, randomized, parallel-group clinical
      trial to compare the efficacy and safety of CELBESTA® and CELEBREX® in patients with
      rheumatoid arthritis. The subject will receive two tablets twice daily for 6 weeks.
    
  